ClinicalTrials.gg
Status unknownNCT05671432Updated Jan 4, 2023

The Study of CM326 in Moderate-to-severe Atopic Dermatitis

A Phase 2 interventional study of CM326 and Placebo in Moderate-to-severe Atopic Dermatitis, sponsored by Keymed Biosciences Co.Ltd. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-01-04.

Sponsored by Keymed Biosciences Co.Ltd · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd — 4 open to participants now, 5 under way, 3 of them phase 3. Dermatitis, Atopic · Keymed Biosciences Co.Ltd.

Planned enrollment
4th of 18
240 · median 170
Started
2022
with 3 others
Phase 2
9 of 18
2 open now
Registered
7th of 18
by date

Among the 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd, this one is the 4th largest by planned enrollment, is one of 4 that started in 2022, is one of 9 in phase 2, and was the 7th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, tolerance, pharmacokinetics, pharmacodynamics, and immunogenicity of CM326 in moderate-severe atopic dermatitis subjects.

Read the detailed description

The study consists of 3 periods, a up-to-4-week Screening Period, a 52-week Treatment Period and a 8-week Safety Follow-up Period.

03

Conditions studied

  • Moderate-to-severe Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • With confirmed Atopic Dermatitis (AD) at the screening.
  • Age ≥ 18 years and ≤ 75 years, male or female.
  • Have the ability to understand the nature of the study and voluntarily sign the .
  • Be able to communicate well with investigators and follow up protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Not enough washing-out period for previous therapy.
  • Received allergen specific immunotherapy (desensitization) within 6 months prior to baseline.
  • Major surgery is planned during the study period.
  • Women who are pregnant or breastfeeding, or who plan to become pregnant during the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Group A

    Group A: CM326, subcutaneous (SC)

    Biological: CM326

  • Experimental
    Group B

    Group A: CM326, subcutaneous (SC)

    Biological: CM326

  • Placebo comparator
    Group C

    Group C: placebo, subcutaneous (SC)

    Other: Placebo

Interventions

  • BiologicalCM326

    CM326 injection

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Proportion of patients with Eczema Area and Severity Index (EASI)-75 (≥75 percent reduction in EASI scores from baseline) at visit 16

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD

    Time frame: at week 16

  2. Proportion of patients with Investigator's Global Assessment (IGA) score = 0-1 and reduction from baseline of ≥2 points at Visit 16

    IGA is a 5-point scale ranging from 0 (clear) to 4 (very severe)

    Time frame: at week 16

07

Study locations

1 of 1 sites recruiting
  • Peking University People's hospital
    Beijing, China
    Recruiting
    • Jianzhong Zhang · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2022; primary completion for Dec 2023, 12 months later.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 12 months is close to that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2022
First posted
Jan 4, 2023
StartEst.
Dec 27, 2022
Primary completionEst.
Dec 30, 2023
CompletionEst.
Dec 30, 2024
Last update
Jan 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05671432
Responsible party
Sponsor
First posted
Jan 4, 2023
Start date
Dec 27, 2022 (estimated)
Primary completion
Dec 30, 2023 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Jan 4, 2023

Study contacts

Qian Jia
Contact
qianjia@keymedbio.com
+862888610620

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocankitug

Start the discussion